ABO-compatible liver allograft antibody-mediated rejection: an update

Current Opinion in Organ Transplantation

Volumn 20, Issue 3, 2015, Pages 314-324

  Demetris, Anthony J ^a   Zeevi, Adriana ^a   Leary, Jacqueline G O ^b  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Acute antibody mediated rejection; C4d; Chronic antibody mediated rejection; Complement dependent cytotoxicity; Donor specific antibodies; Orthotopic liver transplant; T cell mediated rejection

Indexed keywords

COMPLEMENT COMPONENT C4D; BLOOD GROUP ABO SYSTEM;

ADULT; ALLOGRAFT; ANTIBODY MEDIATED REJECTION; CAPILLARITIS; CAPILLARY ENDOTHELIAL CELL; CHOLESTASIS; CHRONIC GRAFT REJECTION; COMPLEMENT DEPENDENT CYTOTOXICITY; CONTROLLED STUDY; EOSINOPHIL; EXPECTATION; FIBROSIS; HEART; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERTROPHY; HYPOCOMPLEMENTEMIA; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; KIDNEY; LIVER CELL; LIVER GRAFT; LONG TERM SURVIVAL; MICROVASCULATURE; MICROVASCULITIS; MORBIDITY; NEUTROPHIL; PRIORITY JOURNAL; REVIEW; SOLID; SWELLING; T LYMPHOCYTE; THROMBOCYTOPENIA; WEANING; ALLOTRANSPLANTATION; BLOOD GROUP ABO SYSTEM; GRAFT REJECTION; IMMUNOLOGY; LIVER TRANSPLANTATION; PHENOTYPE;

ABO BLOOD-GROUP SYSTEM; ALLOGRAFTS; GRAFT REJECTION; HUMANS; LIVER TRANSPLANTATION; PHENOTYPE; TRANSPLANTATION, HOMOLOGOUS;

EID: 84978604361     PISSN: 10872418     EISSN: 15317013     Source Type: Journal    
DOI: 10.1097/MOT.0000000000000194     Document Type: Review

References (136)

1. Demetris AJ, Nakamura K, Yagihashi A, et al. A clinicopathological study of human liver allograft recipients harboring preformed IgG lymphocytotoxic antibodies. Hepatology 1992; 16:671–681.
2. Manez R, Kelly RH, Kobayashi M, et al. Immunoglobulin G lymphocytotoxic antibodies in clinical liver transplantation: studies toward further defining their significance. Hepatology 1995; 21:1345–1352.
3. Doyle HR, Marino IR, Morelli F, et al. Assessing risk in liver transplantation. Special reference to the significance of a positive cytotoxic crossmatch. Ann Surg 1996; 224:168–177.
4. Andres GA, Ansell ID, Halgrimson CG, et al. Immunopathological studies of orthotopic human liver allografts. Lancet 1972; 1:275–280.
5. Gugenheim J, Amorosa L, Gigou M, et al. Specific absorption of lymphocytotoxic alloantibodies by the liver in inbred rats. Transplantation 1990; 50:309–313.
6. Gugenheim J, Charpentier B, Gigou M, et al. Delayed rejection of heart allografts after extracorporeal donor-specific liver hemoperfusion. Role of Kupffer cells. Transplantation 1988; 45:628–632.
7. Saidman SL, Duquesnoy RJ, Demetris AJ, et al. Combined liver-kidney transplantation and the effect of preformed lymphocytotoxic antibodies. Transpl Immunol 1994; 2:61–67.
8. Eid A, Moore SB, Wiesner RH, et al. Evidence that the liver does not always protect the kidney from hyperacute rejection in combined liver-kidney transplantation across a positive lymphocyte crossmatch. Transplantation 1990; 50:331–334.
9. Karruppan S, Ericzon BG, Moller E. Relevance of a positive crossmatch in liver transplantation. Transplant Int 1991; 4:18–25.
10. Takaya S, Bronsther O, Iwaki Y, et al. The adverse impact on liver transplantation of using positive cytotoxic crossmatch donors. Transplantation 1992; 53:400–406.
11. Nikaein A, Backman L, Jennings L, et al. HLA compatibility and liver transplant outcome. Improved patient survival by HLA and cross-matching. Transplantation 1994; 58:786–792.
12. Bathgate AJ, McColl M, Garden OJ, et al. The effect of a positive T-lymphocytotoxic crossmatch on hepatic allograft survival and rejection. Liver Transpl Surg 1998; 4:280–284.
13. Knechtle SJ, Kolbeck P, Tsuchimoto S, et al. Hyperacute rejection of liver transplants in rats. Curr Surg 1986; 43:303–305.
14. Knechtle SJ, Kolbeck PC, Tsuchimoto S, et al. Hepatic transplantation into sensitized recipients. Demonstration of hyperacute rejection. Transplantation 1987; 43:8–12.
15. Takaya S, Duquesnoy R, Iwaki Y, et al. Positive crossmatch in primary human liver allografts under cyclosporine or FK 506 therapy. Transplant Proc 1991; 23:396–399.
16. Daar AS, Fuggle SV, Fabre JW, et al. The detailed distribution of HLA-A, B, C antigens in normal human organs. Transplantation 1984; 38:287–292.
17. Daar AS, Fuggle SV, Fabre JW, et al. The detailed distribution of MHC Class II antigens in normal human organs. Transplantation 1984; 38:293–298.
18. Lautenschlager I, Taskinen E, Inkinen K, et al. Distribution of the major histocompatibility complex antigens on different cellular components of human liver. Cell Immunol 1984; 85:191–200.
19. Demetris AJ, Lasky S, Thiel DHV, et al. Induction of DR/IA antigens in human liver allografts: an immunocytochemical and clinicopathologic analysis of twenty failed grafts. Transplantation 1985; 40:504–509.
20. Ballardini G, Bianchi FB, Mirakian R, et al. HLA-A,B,C, HLA-D/DR and HLA-D/DQ expression on unfixed liver biopsy sections from patients with chronic liver disease. Clin Exp Immunol 1987; 70:35–46.
21. Barbatis C, Kelly P, Greveson J, et al. Immunocytochemical analysis of HLA class II (DR) antigens in liver disease in man. J Clin Pathol 1987; 40:879–884.
22. Steinhoff G, Wonigeit K, Pichlmayr R. Analysis of sequential changes in major histocompatibility complex expression in human liver grafts after transplantation. Transplantation 1988; 45:394–401.
23. Gouw AS, Huitema S, Grond J, et al. Early induction of MHC antigens in human liver grafts. An immunohistologic study. Am J Pathol 1988; 133: 82–94.
24. Steinhoff G, Wonigeit K, Schafers HJ, Haverich A. Sequential analysis of monomorphic and polymorphic major histocompatibility complex antigen expression in human heart allograft biopsy specimens. J Heart Transplant 1989; 8:360–370.
25. Steinhoff G. Major histocompatibility complex antigens in human liver transplants. J Hepatol 1990; 11:9–15.
26. Hubscher SG, Adams DH, Elias E. Changes in the expression of major histocompatibility complex class II antigens in liver allograft rejection. J Pathol 1990; 162:165–171.
27. Terada T, Nakanuma Y, Hoso M, Obata H. Expression of HLA-DR antigen on hepatic vascular endothelial cells in idiopathic portal hypertension. Clin Exp Immunol 1991; 84:303–307.
28. Terada T, Nakanuma Y, Obata H. HLA-DR expression on the microvasculature of portal tracts in idiopathic portal hypertension. Immunohistochemical characteristics and relation to portal phlebosclerosis. Arch Pathol Lab Med 1991; 115:993–997.
29. Devaiah BN, Singer DS. CIITA and its dual roles in MHC gene transcription. Front Immunol 2013; 4:476.
30. Pisapia L, Pozzo GD, Barba P, et al. Contrasting effects of IFNalpha on MHC class II expression in professional vs. nonprofessional APCs: Role of CIITA type IV promoter. Results Immunol 2012; 2:174–183.
31. Valenzuela NM, McNamara JT, Reed EF. Antibody-mediated graft injury: complement-dependent and complement-independent mechanisms. Curr Opin Organ Transplant 2014; 19:33–40.
32. Valenzuela NM, Reed EF. Antibodies in transplantation: the effects of HLA and non-HLA antibody binding and mechanisms of injury. Methods Mol Biol 2013; 1034:41–70.
33. Valenzuela NM, Mulder A, Reed EF. HLA class I antibodies trigger increased adherence of monocytes to endothelial cells by eliciting an increase in endothelial P-selectin and, depending on subclass, by engaging FcgammaRs. J Immunol 2013; 190:6635–6650.
34. O’Leary JG, Kaneku H, Jennings L, et al. Donor-specific alloantibodies are associated with fibrosis progression after liver transplantation in hepatitis C virus-infected patients. Liver Transpl 2014; 20:655–663.
35. Lee SJ, Qin H, Benveniste EN. The IFN-gamma-induced transcriptional program of the CIITA gene is inhibited by statins. Eur J Immunol 2008; 38:2325–2336.
36. Nandan D, Reiner NE. TGF-beta attenuates the class II transactivator and reveals an accessory pathway of IFN-gamma action. J Immunol 1997; 158:1095–1101.
37. Starzl TE, Demetris AJ, Todo S. Evidence of hyperacute rejection of human liver grafts: the case of the canary kidneys. Clin Transpl 1989; 3: 37–45.
38. Demetris AJ, Murase N, Nakamura K, et al. Immunopathology of antibodies as effectors of orthotopic liver allograft rejection. Semin Liver Dis 1992; 12:51–59.
39. Gugenheim J, Houssin D, Tamisier D, et al. Spontaneous long-term survival of liver allografts in inbred rats. Influence of hepatectomy of the recipient’s own liver. Transplantation 1981; 32:445–450.
40. Gugenheim J, Le Thai B, Rouger P, et al. Relationship between the liver and lymphocytotoxic alloantibodies in inbred rats. Specific absorption by nonparenchymal liver cells. Transplantation 1988; 45:474–478.
41. Astarcioglu I, Gugenheim J, Crafa F, et al. Hyperacute rejection of liver allografts in sensitized rats: role of nonparenchymal liver cells. J Surg Res 1995; 58:182–188.
42. Geissler EK, Graeb C, Tange S, et al. Effective use of donor MHC class I gene therapy in organ transplantation: prevention of antibody-mediated hyperacute heart allograft rejection in highly sensitized rat recipients. Hum Gene Ther 2000; 11:459–469.
43. Demetris AJ, Isse K. Tissue biopsy monitoring of operational tolerance in liver allograft recipients. Curr Opin Organ Transplant 2013; 18:345–353.
44. Muczynski KA, Ekle DM, Coder DM, Anderson SK. Normal human kidney HLA-DR-expressing renal microvascular endothelial cells: characterization, isolation, and regulation of MHC class II expression. J Am Soc Nephrol 2003; 14:1336–1348.
45. Page C, Rose M, Yacoub M, Pigott R. Antigenic heterogeneity of vascular endothelium. Am J Pathol 1992; 141:673–683.
46. Astarcioglu I, Cursio R, Reynes M, Gugenheim J. Increased risk of antibody-mediated rejection of reduced-size liver allografts. J Surg Res 1999; 87: 258–262.
47. Shiraishi M, Csete ME, Yasunaga C, et al. Regeneration-induced accelerated rejection in reduced-size liver grafts. Transplantation 1994; 57:336–340.
48. DeLeve LD. Liver sinusoidal endothelial cells in hepatic fibrosis. Hepatology 2015; DOI: 10.1002/hep.27376.
49. Liu X, Xu J, Brenner DA, Kisseleva T. Reversibility of liver fibrosis and inactivation off Fibrogenic myofibroblasts. Curr Pathobiol Rep 2013; 1:209–214.
50. O’Leary JG, Kaneku H, Demetris AJ, et al. Antibody-mediated rejection as a contributor to previously unexplained early liver allograft loss. Liver Transpl 2014; 20:218–227.
51. O’Leary JG, Kaneku H, Jennings LW, et al. Preformed class II donor-specific antibodies are associated with an increased risk of early rejection after liver transplantation. Liver Transpl 2013; 19:973–980.
52. Al-Sibae MR, Koffron AJ, Raofi V. Does a positive pretransplant crossmatch affect long-term outcome in liver transplantation? Transplantation 2011; 91:261–262.
53. Chan KM, Lee CS, Wu TJ, et al. Clinical perspective of acute humoral rejection after blood type-compatible liver transplantation. Transplantation 2011; 91:e29–e30.
54. Ruiz R, Tomiyama K, Campsen J, et al. Implications of a positive crossmatch in liver transplantation: a 20-year review. Liver Transpl 2012; 18:455–460.
55. Lunz J, Ruppert KM, Cajaiba MM, et al. Re-examination of the lymphocytotoxic crossmatch in liver transplantation: can C4d stains help in monitoring? Am J Transplant 2012; 12:171–182.
56. Taner T, Gandhi MJ, Sanderson SO, et al. Prevalence, course and impact of HLA donor-specific antibodies in liver transplantation in the first year. Am J Transplant 2012; 12:1504–1510.
57. O’Leary JG, Michelle Shiller S, Bellamy C, et al. Acute liver allograft antibody-mediated rejection: an inter-institutional study of significant histopathological features. Liver Transpl 2014; 20:1244–1255.
58. Musat AI, Pigott CM, Ellis TM, et al. Pretransplant donor-specific anti-HLA antibodies as predictors of early allograft rejection in ABO-compatible liver transplantation. Liver Transpl 2013; 19:1132–1141.
59. Dar W, Agarwal A, Watkins C, et al. Donor-directed MHC class I antibody is preferentially cleared from sensitized recipients of combined liver/kidney transplants. Am J Transplant 2011; 11:841–847.
60. O’Leary JG, Gebel HM, Ruiz R, et al. Class II alloantibody and mortality in simultaneous liver-kidney transplantation. Am J Transplant 2013; 13:954–960.
61. Kaneku H, O’Leary JG, Banuelos N, et al. De novo donor-specific HLA antibodies decrease patient and graft survival in liver transplant recipients. Am J Transplant 2013; 13:1541–1548.
62. Del Bello A, Congy-Jolivet N, Muscari F, et al. Prevalence, incidence and risk factors for donor-specific anti-HLA antibodies in maintenance liver transplant patients. Am J Transplant 2014; 14:867–875.
63. Kaneku H, O’Leary JG, Taniguchi M, et al. Donor-specific human leukocyte antigen antibodies of the immunoglobulin G3 subclass are associated with chronic rejection and graft loss after liver transplantation. Liver Transpl 2012; 18:984–992.
64. O’Leary J, Kaneku H, Banuelos N, et al. Impact of IgG3 subclass and C1qfixing donor specific antibodies on rejection and survival in liver transplantation. Am J Transplant 2015. [Epub ahead of print]
65. Castillo-Rama M, Sebagh M, Sasatomi E, et al. Plasma cell hepatitis’’ in liver allografts: identification and characterization of an IgG4-Rich cohort. Am J Transplant 2013; 13:2966–2977.
66. Venick RS, McDiarmid SV, Farmer DG, et al. Rejection and steroid dependence: unique risk factors in the development of pediatric posttransplant de novo autoimmune hepatitis. Am J Transplant 2007; 7:955–963.
67. Sebagh M, Castillo-Rama M, Azoulay D, et al. Histologic findings predictive of a diagnosis of de novo autoimmune hepatitis after liver transplantation in adults. Transplantation 2013; 96:670–678.
68. Mendes F, Couto CA, Levy C. Recurrent and de novo autoimmune liver diseases. Clin Liver Dis 2011; 15:859–878.
69. Czaja AJ, Manns MP. Advances in the diagnosis, pathogenesis, and management of autoimmune hepatitis. Gastroenterology 2010; 139:58–72; e54.
70. Hubscher SG. What is the long-term outcome of the liver allograft? J Hepatol 2011; 55:702–717.
71. Inui A, Sogo T, Komatsu H, et al. Antibodies against cytokeratin 8/18 in a patient with de novo autoimmune hepatitis after living-donor liver transplantation. Liver Transplantation 2005; 11:504–507.
72. Huguet S, Vinh J, Johanet C, et al. Identification by proteomic tool of atypical antiliver/kidney microsome autoantibodies targets in de novo autoimmune hepatitis after liver transplantation. Ann N Y Acad Sci 2007; 1109:345–357.
73. Dragun D, Catar R, Philippe A. Non-HLA antibodies in solid organ transplantation: recent concepts and clinical relevance. Curr Opin Organ Transplant 2013; 18:430–435.
74. Ohe H, Uchida Y, Yoshizawa A, et al. Association of anti-human leukocyte antigen and anti-angiotensin ii type 1 receptor antibodies with liver allograft fibrosis after immunosuppression withdrawal. Transplantation 2014; 98: 1105–1111.
75. Djamali A, Kaufman DB, Ellis TM, et al. Diagnosis and management of antibody-mediated rejection: current status and novel approaches. Am J Transplant 2014; 14:255–271.
76. Farkash EA, Colvin RB. Diagnostic challenges in chronic antibody-mediated rejection. Nature reviews. Nephrology 2012; 8:255–257.
77. Drachenberg CB, Papadimitriou JC. Endothelial injury in renal antibody-mediated allograft rejection: a schematic view based on pathogenesis. Transplantation 2013; 95:1073–1083.
78. Smith RN, Colvin RB. Chronic alloantibody mediated rejection. Semin Immunol 2012; 24:115–121.
79. Cousens LP, Najafian N, Mingozzi F, et al. In vitro and in vivo studies of IgG-derived Treg epitopes (Tregitopes): a promising new tool for tolerance induction and treatment of autoimmunity. J Clin Immunol 2013; 33 (Suppl 1): S43–S49.
80. Platt JL. Antibodies in transplantation. Discov Med 2010; 10:125–133.
81. Chang AT, Platt JL. The role of antibodies in transplantation. Transplant Rev 2009; 23:191–198.
82. Leffell MS, Zachary AA. Antiallograft antibodies: some are harmful, some can be overcome, and some may be beneficial. Discov Med 2010; 9:478–484.
83. Narayanan K, Jaramillo A, Phelan DL, Mohanakumar T. Preexposure to sub-saturating concentrations of HLA class I antibodies confers resistance to endothelial cells against antibody complement-mediated lysis by regulating Bad through the phosphatidylinositol 3-kinase/Akt pathway. Eur J Immunol 2004; 34:2303–2312.
84. Adair A, Mitchell DR, Kipari T, et al. Peritubular capillary rarefaction and lymphangiogenesis in chronic allograft failure. Transplantation 2007; 83: 1542–1550.
85. Escaned J, Flores A, Garcia-Pavia P, et al. Assessment of microcirculatory remodeling with intracoronary flow velocity and pressure measurements: validation with endomyocardial sampling in cardiac allografts. Circulation 2009; 120:1561–1568.
86. Greene AS, Tonellato PJ, Zhang Z, et al. Effect of microvascular rarefaction on tissue oxygen delivery in hypertension. Am J Physiol 1992; 262:H1486–H1493.
87. Li X, Sun Q, Zhang M, et al. Capillary dilation and rarefaction are correlated with intracapillary inflammation in antibody-mediated rejection. J Immunol Res 2014; 2014:582902.
88. Shimizu A, Yamada K, Sachs DH, Colvin RB. Persistent rejection of peritubular capillaries and tubules is associated with progressive interstitial fibrosis. Kidney Int 2002; 61:1867–1879.
89. Dormond O, Dufour M, Seto T, et al. Targeting the intragraft microenvironment and the development of chronic allograft rejection. Hum Immunol 2012; 73:1261–1268.
90. Bruneau S, Woda CB, Daly KP, et al. Key features of the intragraft micro-environment that determine long-term survival following transplantation. Front Immunol 2012; 3:54.
91. Furuya T, Murase N, Nakamura K, et al. Preformed lymphocytotoxic antibodies: the effects of class, titer and specificity on liver vs. heart allografts. Hepatology 1992; 16:1415–1422.
92. Kawagishi N, Satomi S. ABO-incompatible living donor liver transplantation: new insights into clinical relevance. Transplantation 2008; 85:1523–1525.
93. Aguilera I, Alvarez-Marquez A, Gentil MA, et al. Antiglutathione S-transferase T1 antibody-mediated rejection in C4d-positive renal allograft recipients. Nephrol Dial Transplant 2008; 23:2393–2398.
94. Hubscher SG. Antibody-mediated rejection in the liver allograft. Curr Opin Organ Transplant 2012; 17:280–286.
95. Kozlowski T, Rubinas T, Nickeleit V, et al. Liver allograft antibody-mediated rejection with demonstration of sinusoidal C4d staining and circulating donor-specific antibodies. Liver Transpl 2011; 17:357–368.
96. Jain A, Demetris AJ, Kashyap R, et al. Does tacrolimus offer virtual freedom from chronic rejection after primary liver transplantation? Risk and prognostic factors in 1048 liver transplantations with a mean follow-up of 6 years. Liver Transpl 2001; 7:623–630.
97. Kakizoe S, Yanaga K, Starzl TE, Demetris AJ. Evaluation of protocol before transplantation and after reperfusion biopsies from human orthotopic liver allografts: considerations of preservation and early immunological injury. Hepatology 1990; 11:932–941.
98. Musat AI, Agni RM, Wai PY, et al. The significance of donor-specific HLA antibodies in rejection and ductopenia development in ABO compatible liver transplantation. Am J Transplant 2011; 11:500–510.
99. Bellamy CO. Complement C4d immunohistochemistry in the assessment of liver allograft biopsy samples: Applications and pitfalls. Liver Transpl 2011; 17:747–750.
100. Matsunaga Y, Terada T. Peribiliary capillary plexus around interlobular bile ducts in various chronic liver diseases: An immunohistochemical and morphometric study. Pathol Int 1999; 49:869–873.
101. Oguma S, Belle S, Starzl TE, Demetris AJ. A histometric analysis of chronically rejected human liver allografts: insights into the mechanisms of bile duct loss: direct immunologic and ischemic factors. Hepatology 1989; 9:204–209.
102. Takemura M, Oguma S, Mori S, et al. Peribiliary vascular diseases in rejected livers; computer-aided three-dimensional reconstruction and morphometry. Transplant Proc 1991; 23:1409–1412.
103. Matsumoto Y, McCaughan GW, Painter DM, Bishop GA. Evidence that portal tract microvascular destruction precedes bile duct loss in human liver allograft rejection. Transplantation 1993; 56:69–75.
104. Miyagawa-Hayashino A, Yoshizawa A, Uchida Y, et al. Progressive graft fibrosis and donor-specific human leukocyte antigen antibodies in pediatric late liver allografts. Liver Transpl 2012; 18:1333–1342.
105. Yamada H, Kondou H, Kimura T, et al. Humoral immunity is involved in the development of pericentral fibrosis after pediatric live donor liver transplantation. Pediatr Transplant 2012; 16:858–865.
106. Demetris AJ, Jaffe R, Tzakis A, et al. Antibody-mediated rejection of human orthotopic liver allografts. A study of liver transplantation across ABO blood group barriers. Am J Pathol 1988; 132:489–502.
107. Bellamy CO, Herriot MM, Harrison DJ, Bathgate AJ. C4d immunopositivity is uncommon in ABO-compatible liver allografts, but correlates partially with lymphocytotoxic antibody status. Histopathology 2007; 50:739–749.
108. Bu X, Zheng Z, Yu Y, et al. Significance of C4d deposition in the diagnosis of rejection after liver transplantation. Transplant Proc 2006; 38:1418–1421.
109. Dankof A, Schmeding M, Morawietz L, et al. Portal capillary C4d deposits and increased infiltration by macrophages indicate humorally mediated mechanisms in acute cellular liver allograft rejection. Virchows Arch 2005; 447: 87–93.
110. Haga H, Egawa H, Fujimoto Y, et al. Acute humoral rejection and C4d immunostaining in ABO blood type-incompatible liver transplantation. Liver Transpl 2006; 12:457–464.
111. Jain A, Mohanka R, Orloff M, et al. Characterization of CD4, CD8, CD56 positive lymphocytes and C4d deposits to distinguish acute cellular rejection from recurrent hepatitis C in postliver transplant biopsies. Clin Transplant 2006; 20:624–633.
112. Krukemeyer MG, Moeller J, Morawietz L, et al. Description of B lymphocytes and plasma cells, complement, and chemokines/receptors in acute liver allograft rejection. Transplantation 2004; 78:65–70.
113. Sakashita H, Haga H, Ashihara E, et al. Significance of C4d staining in ABO-identical/compatible liver transplantation. Mod Pathol 2007; 20:676–684.
114. Sawada T, Shimizu A, Kubota K, et al. Lobular damage caused by cellular and humoral immunity in liver allograft rejection. Clin Transplant 2005; 19:110–114.
115. Troxell ML, Higgins JP, Kambham N. Evaluation of C4d staining in liver and small intestine allografts. Arch Pathol Lab Med 2006; 130:1489–1496.
116. Bouron-Dal Soglio D, Rougemont AL, Herzog D, et al. An immunohistochemical evaluation of C4d deposition in pediatric inflammatory liver diseases. Hum Pathol 2008; 39:1103–1110.
117. Aguilera I, Sousa JM, Gavilan F, et al. Complement component 4d immunostaining in liver allografts of patients with de novo immune hepatitis. Liver Transpl 2011; 17:779–788.
118. Schmeding M, Dankof A, Krenn V, et al. C4d in acute rejection after liver transplantation: a valuable tool in differential diagnosis to hepatitis C recurrence. Am J Transplant 2006; 6:523–530.
119. Silva MA, Mirza DF, Murphy N, et al. Intrahepatic complement activation, sinusoidal endothelial injury, and lactic acidosis are associated with initial poor function of the liver after transplantation. Transplantation 2008; 85:718–725.
120. Martelius T, Halme L, Arola J, et al. Vascular deposition of complement C4d is increased in liver allografts with chronic rejection. Transpl Immunol 2009; 21:244–246.
121. Hoshino J, Kaneku H, Everly MJ, et al. Using donor-specific antibodies to monitor the need for immunosuppression. Transplantation 2012; 93:1173–1178.
122. Feng S, Demetris AJ, Ekong U, et al. Serum and Tissue DSA Subclass, Stellate and Endothelial Phenotype Monitoring in ITN029ST Tolerance Pediatric LIver Transplant Recipients over 5R Years of Follow-up. (Abstract #O-47) In: Joint International Conference of ILTS, ELITA & LICAGE; London: 4–7 June 2014.
123. Banff Working G, Demetris AJ, Adeyi O, et al. Liver biopsy interpretation for causes of late liver allograft dysfunction. Hepatology 2006; 44:489–501.
124. Banff Working G. Importance of liver biopsy findings in immunosuppression management: biopsy monitoring and working criteria for patients with operational tolerance. Liver Transpl 2012; 18:1154–1170.
125. Demetris AJ, Lunz JG 3rd, Randhawa P, et al. Monitoring of human liver and kidney allograft tolerance: a tissue/histopathology perspective. Transpl Int 2009; 22:120–141.
126. Benitez C, Londono MC, Miquel R, et al. Prospective multicenter clinical trial of immunosuppressive drug withdrawal in stable adult liver transplant recipients. Hepatology 2013; 58:1824–1835.
127. Feng S, Ekong UD, Lobritto SJ, et al. Complete immunosuppression withdrawal and subsequent allograft function among pediatric recipients of parental living donor liver transplants. JAMA 2012; 307:283–293.
128. Wong T, Nouri-Aria KT, Devlin J, et al. Tolerance and latent cellular rejection in long-term liver transplant recipients. Hepatology 1998; 28:443–449.
129. Bohne F, Martinez-Llordella M, Lozano JJ, et al. Intra-graft expression of genes involved in iron homeostasis predicts the development of operational tolerance in human liver transplantation. J Clin Invest 2012; 122:368–382.
130. Yoshitomi M, Koshiba T, Haga H, et al. Requirement of protocol biopsy before and after complete cessation of immunosuppression after liver transplantation. Transplantation 2009; 87:606–614.
131. Egawa H, Miyagawa-Hayashino A, Haga H, et al. Non-inflammatory centrilobular sinusoidal fibrosis in pediatric liver transplant recipients under tacrolimus withdrawal. Hepatol Res 2012; 42:895–903.
132. Rockey DC, Caldwell SH, Goodman ZD, et al. Liver biopsy. Hepatology 2009; 49:1017–1044.
133. Sanada Y, Matsumoto K, Urahashi T, et al. Protocol liver biopsy is the only examination that can detect mid-term graft fibrosis after pediatric liver transplantation. World J Gastroenterol 2014; 20:6638–6650.
134. Paterno F, Shiller M, Tillery G, et al. Bortezomib for acute antibody-mediated rejection in liver transplantation. Am J Transplant 2012; 12:2526–2531.
135. Lee CF, Eldeen FZ, Chan KM, et al. Bortezomib is effective to treat acute humoral rejection after liver transplantation. Transplant Proc 2012; 44:529–531.
136. Isse K, Lesniak A, Grama K, et al. Digital transplantation pathology: combining whole slide imaging, multiplex staining and automated image analysis. Am J Transpl 2012; 12:27–37.